Skip to main content

Table 5 Annual direct medical costs attributable to T2D according to main resource categories among study participants in Bahrain

From: Type 2 diabetes and healthcare resource utilisation in the Kingdom of Bahrain

 For each patientTotal populationFor each patientTotal population
BHD
(95% CI)
USD
(95% CI)
Million BHD
(95% CI)
Million USD
(95% CI)
Admissions690
(485–895)
1831
(1287–2374)
62.2
(43.7–80.6)
165.0
(116.0–214.0)
Procedures173
(122–225)
460
(323–598)
15.6
(11.0–20.3)
41.5
(29.1–53.9)
Outpatient visits101
(94–108)
269
(250–288)
9.1
(8.5–9.8)
24.2
(22.5–26.0)
Laboratory tests82
(75–89)
218
(200–235)
7.4
(6.8–8.0)
19.6
(18.0–21.2)
Oral antidiabetic medicine49
(46–51)
130
(122–137)
4.4
(4.2–4.6)
11.7
(11.0–12.3)
Insulin and other injectables42
(34–51)
113
(91–134)
3.8
(3.1–4.6)
10.2
(8.2–12.1)
Other oral medicine21
(10–24)
57
(49–65)
1.9
(1.7–2.2)
5.1
(4.4–5.8)
Self-monitoring2
(945–1379)
6
(4–9)
0.2
(0.13–0.3)
0.56
(0.34–0.78)
Total costsa1162
(945–1379)
3084
(2507–3659)
104.7
(85.1–124.2)
277.8
(225.9–329.7)
  1. Self-monitoring covers lancets and strips; Oral medicine covers oral antidiabetic medicine, blood pressure-lowering medicine and lipid-lowering medicine; Procedures covers cardiac catheterisation, laser treatment and cataract surgery; M: million
  2. a Due to rounding, some totals may not correspond to the sum of the separate figures